Universidad Iberoamericana
Santo Domingo, Nacional, 51000, Dominican Republic
NCT Number: NCT05143411
Adolescents with type 1 diabetes mellitus (T1 DM) tend to have poor metabolic control. There are no mobile applications in our language in our environment, and patients are accessible in addition to the difficulties involved in these manual calculations. One way to bridge the knowledge gaps in T1 DM self-management is by using technology to optimize metabolic control and reduce the risks of associated comorbidities, with a mobile application that helps optimize decision-making in self-management. This research aims to help people with type 1 diabetes to change the glycemic blood levels and to be able to calculate the food together with the amount of insulin with food from the region. To evaluate the acceptability and effectiveness of the application, the investigators will carry out a pilot evaluation test. The participants in this pilot test will be 20 people between 14 and 18 years old with T1DM, users of the pediatric diabetology service of the National Institute of Diabetes, Endocrinology, and Nutrition (INDEN).
Looking for future studies?
Notify Me14 year–18 year
All sexes
Interventional
Not applicable
Santo Domingo, Nacional, 51000, Dominican Republic
Metabolic lack of control in patients with type 1 diabetes Mellitus (T1DM) leads to kidney failure, non-traumatic amputations, blindness, and reduced life expectancy. In addition, determining the content of macronutrients in food is not the domain of many patients, particularly adolescents, or some physicians, making insulin adjustment difficult, one of the main failures of optimal metabolic control. One way to bridge the knowledge gaps in T1D self-management is by using technology to optimize metabolic control and reduce the risks of associated comorbidities, with a mobile application that helps optimize decision-making in self-management. And a reduction of complications in adolescents (14-18 years) with T1DM. This project aims to develop this application that contributes to decision-making and the reduction of comorbidities of adolescents with T1DM, following the policies of the Dominican state through Digital systems, together with its educational mission, technological access, and national competitiveness.
There are no mobile applications in use in the Dominican Republic for the self-management of chronic diseases. Therefore, the investigators have designed a mobile application with a postprandial insulin bolus calculator. In addition, the developers has added a list of foods from the region where users can select their foods and adjust them with the amount of insulin to metabolize them. The methodology includes a mixed approach (qualitative and quantitative) before starting the study and after three months of using the application.
To evaluate the acceptability and effectiveness of the application, we will carry out a pilot evaluation test. The participants in this pilot test will be 20 people between 14 and 18 years old with T1DM, users of INDEN. This experimental study has a systematized probabilistic sample from the center's master list. They were randomized, not controlled. Therefore, the participants are users of the pediatric diabetology service, and included prior explanation and approval of informed consent. These 20 participants will be recruited, ensuring the equitable distribution between gender and sociodemographic data of the mentioned group while maintaining the intention to treat.
Inclusion criteria
-Patients between 14-18 years old with diabetes type 1.
Exclusion criteria
The investigators invited the participants to select foods and routinely use the mobile app's insulin bolus calculator for three months.
For data analysis, the researchers are going to perform the normality test for numerical variables. Then, the categorical data presentation will be with frequencies and percentages tables and the quantitative data as means and standard deviation, and use a non-Gaussian distribution, Kruskal-Wallis and Mann-Whitney tests.
The primary endpoint, HbA1c at the beginning of the study and the end of the third month of use of the application, will be analyzed with Kruskal-Wallis and Mann-Whitney tests and for pre-test and post-test comparisons of the study group, and the multifactorial analysis of variance (ANCOVA), baseline HbA1c level and at 3 months after using the application, taking into account age as covariates. The investigators are going to use for statistical analysis the Statistical Package for the Social Sciences (SPSS), and Excel of the data obtained.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
we are going to verify glucose levels before (pre) and after (post) the use of the mobile application.
Other names: Post-Test
Time frame: Day 01, Month 01
We expect to find changes in glucose levels before each main meal
Time frame: Day 01, month 3
we expect to find changes in variations of coefficients
Universidad Iberoamericana
Other
Evaluation of a Mobile Application to Optimize Decision-making in Self-management and Reduction of Complications in Persons With Type 1 Diabetes
Acronym: DM-BLUE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06238778
Autoimmune Diseases, Diabetes Mellitus
Huntington Beach, California, United States
View Trial DetailsNCT06236256
Autoimmune Diseases, Diabetes Mellitus
Ramat Gan, Israel
View Trial DetailsNCT07711275
Autoimmune Diseases, Diabetes Mellitus
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03938324
Anemia, Anemia, Hemolytic
Durham, North Carolina, United States
View Trial Details